Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection

Human papillomavirus (HPV) proteins E6 & E7 are considered to be the constitutively expressed neoantigens in a vast majority of cervical squamous intraepithelial lesions and cancers. Data available from in-vitro, animal, and small clinical trials suggest that the immunological properties of interferon gamma might enhance early viral protein presentation, thus stimulating a cytotoxic response. In order to study this effect in vivo we undertook a trial in which 20 women with a definite diagnosis of cervical intraepithelial neoplasia (CIN) grade I or II with coexistent high-risk HPV infection (detected by the Hybrid Capture System) underwent four months observation followed by intracervical administration of INFgamma in cases without spontaneous regression (17 cases). Human recombinant interferon gamma 1-b (Imukin) was administered intracervically four times in equal doses in two-day intervals to a total dose of 6,000,000 IU. The results of therapy were verified by punch biopsy evaluation and HPV-DNA testing two months after completion, and revealed a complete response in nine women (complete regression of CIN and remission of HPV infection in 53% of treated cases) and partial response in four cases (lower grade of CIN or/and remission of HPV infection--23.5%). The differences between spontaneous (before treatment) and treatment-related regressions were significant at p < 0.05. We conclude that in selected cases (mainly young women who have not completed their procreation and are compliant with the therapy) a conservative approach to CIN management with intracervical IFNgamma injections seems to be a valuable method.

Cervical intraepithelial neoplasia (CIN); Conservative treatment; Interferon gamma (IFNy).

[1] Morelli A. E., Sananes C., DiPaola G., Paredes A., Fainboirn L.: "Relationship between types of human papillomavirus and Langerhans'cells in cervical condylorna and intraepithelial neoplasia". Am. J. Clin. Pathol., 1993, 99, 200.

[2] Keating P. J., Crornrne F. V., Duggan-Keen M., Snijders P. J. F., Walboorners J. M. M., Hunter R. D.: "Frequency of down-regulation of individual HLA-A and -8 alleles in cervical carcinomas in relation to TAP-1 expression". Br. J. Cancer, 1995, 72, 405.

[3] Hilders C. G. J. M., Houbiers J. G. A., Krul E. J. T., Fleuren G. J.: "The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma". Am. J. Clin. Pathol., 1994, 101, 5.

[4] Stern P. L., Duggan-Keen M.: "MHC expression in the natural history of cervical cancer". In: "Human papillomavirus and cervical cancer - biology and immunology". Stern P. L. & Stanley M. A. (eds.). Oxford, Oxford University Press, 1994.

[5] Gemignani M., Maiman M., Fruchter R. G., Arrastia C. D., Gibbon D., Ellison T.: "CD4 lymphocytes in women with invasive and preinvasive cervical neoplasia". Gynecol. Oncol., 1995, 59, 364.

[6] Williams J. G., Jurkovich G. J., Maier R. V.: "Interferon gamma: a key immunoregulatory lymphokine". J. Surg. Res., 1993, 54, 79.

[7] Huizinga T. W. J., van der Schoot C. E., Roos D.: "Induction of neutrophil Fe-gamma receptor I expression can be used as a marker for biologic activity of recombinant interferon-gamma in vivo". Blood., 1991, 77, 2088.

[8] Abbas A. K., Lichtman A. H., Pober J. S.: "Cellular and MolecuJar Immunology". 2nd ed., Philadelphia, W.B. Saunders Company, 1994, 262.

[9] Sikorski M.，加bek H., Wiktor H.: "Response rate to interferron gamma local treatment of cervical intraepithelial neoplasia" . Proc. Balkan Congress of Oncology, Athens, Jul.3-7, Bologna, Monduzzi Editore, 1996.

[10] Iwasaka T., Hayashi Y., Yokoyama M., Hachisuga T., Sugimori H.: "Interferon gamma treatment for cervical intraepithelial neoplasia". Gynecol.Oncol., 1990, 37, 96.

[11] Schneider A., Grubert T., Kirchmayr R., Wagner D., Papendick U., Schlunck G.: "Efficacy trial of topically administered interferon gamma-l b gel in comparison to laser treatment in cervical intraepithelial neoplasia". Arch. Gynecol. Obstet., 1995, 256, 75.

[12] Meneguzzi G., Cerni C., Kieny M. P., Lathe R. : "Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and ET'. Virology, 1991, 181, 62.

[13] Choo Y. C., Hsu C., Seto W. H.: "Intravaginal application of leukocyte interferon gel in the treatment of cervical intraepithelial neoplasia". Arch. Gynecol., 1985, 237, 51.

[14] Dunham A. M., McCartney J. C., McCance D. J., Taylor R. W: "Effect of perilesional injection of alpha-interferon on cervical intraepithelial neoplasia and associated human papillomavirus infection". J. R. Soc. Med., 1990, 83, 490.

[15] Kirby P. K., Kiviat N., Beckman A., Wells D., Sherwin S., Corey L.: "Tolerance and efficacy of recombinant human interferon ganuna in the treatment of refractory genital warts". Am. J. Med., 1988, 85, 183.

[16] Zouboulis C. C., Stadler R., Ikenberg H., Orfanos C. E.: "Shortterm systemic recombinant interferon gamma treatment is ineffective in recalcitrant condylomata acuminata". J. Am. Acad. Dermatol., 1991, 24, 302.

[17] Kirby P. K., Corey L.: "Interferon gamma for human papillomavirus infection". In: "Anti-infective Applications of Interferon Gamma". Jaffe H.S., Bucalo L.R., Sherwin S.A. (eds.). Basel, Marcel Dekker, Inc., 1992.

[18] Stauss H. J., Beverley P. C. L.: "The search for cell-mediated immunity to HPV: prospects for vaccine design". In: "Human Papillomavirus and Cervical Cancer. Biology and Immunology". Stern P. L., Stanley M. A. (eds.). Oxford, Oxford Medical Press, 1994.

[19] Quillet A., Presse F., Marchiol-Foumigault C., Harel-Bellan A., Benbunan M., Poegh H., Fradelizi D.: "Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression". J. Immunol., 1988, 141, 17.

[20] Ellerrhorst J. A., Kilbourne R. G., Amato R. J., Zukiwski A. A., Jones E., Logothetis C. J.: "Phase II trail of low dose gamma interferon in metastatic renal cell carcinoma". J. Urology, 1994, 152, 841.

[21] Frost L., Skajaa K., Hvidman L. E., Fay S. J., Larsen P. M.: "No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia". Br. J. Obstet. Gynecol., 1990, 97, 626.

[22] Grismondi G. L., Marini A., Scivoli L., Rigoni I.: "Human fibroblast interferon therapy alone and human fibroblast interferon combined with thymostimulin in genital papillomavirus infection associated with cervical intraepithelial neoplasia". Minerva Ginecol., 1991, 43, 581.